Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
53,512,954,839
-
Total 13F shares
-
322,783
-
Share change
-
+141,457
-
Total reported value
-
$393,794
-
Price per share
-
$1.22
-
Number of holders
-
14
-
Value change
-
+$114,040
-
Number of buys
-
5
-
Number of sells
-
2
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) as of Q4 2024
As of 31 Dec 2024,
Akari Therapeutics Plc - Ordinary Shares, $0.0001 par value (AKTX) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
322,783 shares.
The largest 10 holders included
Palo Alto Investors LP, Omnia Family Wealth, LLC, Cerity Partners LLC, RENAISSANCE TECHNOLOGIES LLC, Cresset Asset Management, LLC, Catalina Capital Group, LLC, Accent Capital Management, LLC, UBS Group AG, BANK OF AMERICA CORP /DE/, and OSAIC HOLDINGS, INC..
This page lists
14
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.